Phase 1, Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer, K36-MCRPC-001
Clinical Trial Grant
Awarded By
K36 Therapeutics
Start Date
January 7, 2026
End Date
January 18, 2031
Awarded By
K36 Therapeutics
Start Date
January 7, 2026
End Date
January 18, 2031